We reviewed medical records of 256 patients to investigate the frequency and characteristics of hemorrhagic cystitis (HC) associated with reduced-intensity stem cell transplantation (RIST) as opposed to conventional stem cell transplantation (CST); 137 patients underwent CST and 119 RIST. Diagnosis of HC was made based on two or more episodes of sterile, macroscopic hematuria with normal coagulation profiles, without any evidence of renal stones or genitourinary malignancy. Actuarial frequency of HC development in RIST group was 7.6% (9/119), which gave a cumulative annual incidence of 11.7%. In CST group, 13 of 137 patients (9.5%) developed HC, giving an estimated annual incidence of 9.7%. The probability of developing HC was similar between the two groups (P ¼ 0.77). The viral etiologies of HC, adenovirus (n ¼ 12) and BK virus (n ¼ 2), were documented in eight patients after RIST and in six after CST. HC was milder and of a shorter duration, with less blood transfusion requirements, in RIST group than in CST group. A multivariate analysis revealed that HC was associated with antiadenovirus antibody positivity in the recipients, total dose of busulfan, and chronic GVHD. Although HC following RIST is less severe than that following CST, it is still a significant problem. Bone Marrow Transplantation (2003) 32, 1089-1095. doi:10.1038/sj.bmt.1704261 Keywords: reduced-intensity stem cell transplantation; hemorrhagic cystitis; adenovirus A new transplantation strategy using nonmyeloablative preparative regimens, or reduced-intensity stem cell transplantation (RIST), was developed to decrease regimenrelated toxicity (RRT), while preserving an adequate antitumor effect.
A new transplantation strategy using nonmyeloablative preparative regimens, or reduced-intensity stem cell transplantation (RIST), was developed to decrease regimenrelated toxicity (RRT), while preserving an adequate antitumor effect. [1] [2] [3] Different pioneering conditioning regimens for RIST have been investigated, such as those including purine analogs [1] [2] [3] [4] [5] and total body irradiation (TBI) combined with potent immunosuppressants. 6 However, no consensus has been reached regarding either conditioning regimens or indications for RIST.
Hemorrhagic cystitis (HC) is a common complication of conventional hematopoietic stem cell transplantation (CST) with myeloablative conditioning regimens. Its manifestations vary from painless microscopic hematuria to severe bladder hemorrhage leading to clot formation within the urinary tract and possible obstructive renal failure. The reported frequency of HC also varies from 7 to 68% of bone marrow transplantation cases. [7] [8] [9] [10] [11] Early HC, defined as HC occurring within 72 h of preparative regimens, has been a common complication of high-dose cyclophosphamide (CY), and its metabolite, acrolein, is considered to be primarily responsible. The routine use of mesna that binds to acrolein, vigorous hydration, and forced diuresis with or without bladder irrigation have successfully eliminated the occurrence of early HC. 12 In contrast, late HC, occurring more than 72 h after preparative regimens, appears to remain common in both CST and RIST. Previously suggested risk factors for late HC include viral infections, busulfan (BU) use, pelvic irradiation, older age at transplantation, allogeneic hematopoietic stem cell transplantation (allo-HSCT), and graft-versushost disease (GVHD). [13] [14] [15] [16] Although the degree of immunosuppression with different GVHD prophylaxis regimens has been reported to affect the incidence and severity of viral HC following CST, little is known about HC following RIST. In the present study, we investigated HC following RIST with regard to its incidence, characteristics, and risk factors, in comparison with those in CST.
Patients and methods

Patients
All of the medical records of the patients who underwent allo-HSCT at National Cancer Center Hospital and Toranomon Hospital between January 1999 and June 2002 were reviewed. There were 256 patients, 161 men and 95 women, with a median age of 45.5 years (range, 1-70).
The primary diseases were acute myeloblastic leukemia (n ¼ 83), chronic myeloblastic leukemia (n ¼ 42), acute lymphoblastic leukemia (n ¼ 26), non-Hodgkin's lymphoma (n ¼ 45), myelodysplastic syndrome (n ¼ 19), solid tumors (n ¼ 18), adult T-cell leukemia/lymphoma (n ¼ 8), and others (n ¼ 15). The hematological malignancies were refractory to cytotoxic chemotherapies in 98 cases and were in remission or sensitive to treatments in the remaining 158 cases. All of the patients with solid tumors were incurable with conventional treatments.
Preparative regimens
In all, 137 patients underwent CST and 119 underwent RIST.
Conventional preparative regimens consisted of CY and TBI (n ¼ 75), 17 BU and CY (n ¼ 41), 18 ara-C 2 g/m 2 for 4 days and CY/TBI (n ¼ 9), and others (n ¼ 12). In the CST group, rabbit antithymocyte globulin (ATG, thymoglobulin; IMTIX-SANGSTAT, Lyons, France) 2.5 mg/kg for 4 consecutive days was added to five patients who were transplanted from one antigen-mismatched unrelated donors.
Reduced-intensity preparative regimens were fludarabine 30 mg/kg for 6 days and CY 60 mg/kg for 2 days (n ¼ 12), fludarabine 30 mg/kg for 6 days and BU 4 mg/kg for 2 days (n ¼ 64), 19 fludarabine 30 mg/kg for 6 days and melphalan 140 mg/m 2 (n ¼ 16), cladribine 0.11 mg/kg for 6 days and BU 4 mg/kg for 2 days (n ¼ 26), 5 and others (n ¼ 1). In the RIST group, rabbit ATG 5 mg/kg for 2 or 4 consecutive days and TBI (mainly 4 Gy) were added to the preparative regimens in 57 and seven patients, respectively.
Stem cell source
In the CST group, 109 patients were transplanted from HLA-identical donors, and 28 from HLA one-locusmismatched donors. A total of 56 patients received G-SCF-mobilized peripheral blood stem cells and 81 received bone marrow. In the RIST group, 98 patients had HLA-identical donors and 21 had mismatched donors. Peripheral blood stem cells were used for 104 patients and bone marrow for 15.
Prophylaxis and treatment of GVHD
Cyclosporine and short-term methotrexate were mainly used for GVHD prophylaxis in the CST group. Most patients in the RIST group received only cyclosporine (3 mg/kg). 5 The diagnosis of GVHD was made by clinical judgment in concert with biopsy of the skin and digestive tract. Acute and chronic GVHD were graded according to the consensus criteria. 20, 21 Grade II-IV acute GVHD was treated with 2 mg/kg/day of methylprednisolone in addition to cyclosporine.
Management of infections
All of the patients stayed in reverse isolation in laminar airflow-equipped rooms, and received prophylaxis with trimethoprim/sulfamethoxazole or pentamidine inhaler, fluoroquinolone, and fluconazole against Pneumocystis carinii, bacterial, and fungal infection, respectively. Herpesvirus prophylaxis with acyclovir was also given as previously described. 22 Cytomegalovirus (CMV) pp65 antigenemia was routinely monitored once a week. When antigenemia was confirmed, pre-emptive therapy with ganciclovir was initiated as previously reported. 23 Neutropenic fever was managed according to the report by Pizzo. 24 
Latent adenovirus infection
Antiadenovirus IgG antibody was examined in 145 patients before HSCT, of whom 24 (16.6%) were seropositive. Of 119 donors tested for antiadenovirus IgG, 35 (29%) were positive. Neither BK virus nor JC virus (JCV) IgG were routinely examined in our hospitals, since these rarely cause HC in Japan. 25, 26 Definition of HC HC was defined as two or more episodes of macroscopic hematuria in sterile urine with normal coagulation status, without any history/evidence of renal stones or genitourinary malignancy. HC was graded according to the following criteria: grade 0, no macroscopic hematuria; grade I, macroscopic hematuria without clots; grade II, macroscopic hematuria with clots; and grade III, macroscopic hematuria with clots and elevated creatinine secondary to urinary tract obstruction.
Urine specimens
Urinalysis was performed at least once a week from the initiation of the preparative regimens until hospital discharge. When macroscopic hematuria developed, urine was subjected to bacterial, fungal, and viral cultures, and polymerase chain reaction (PCR) for adenovirus.
Viral cultures and shell vial method targeting adenovirus
After red blood cells were removed as needed, 2 ml of urine was centrifuged overnight at 20 000 g, and the sediment was cocultured with Hep-2 cells for up to 4 weeks. If virus grew, it was typed and confirmed.
After removing red blood cells as needed, we added 1 ml of urine to Hep-2 cells, which were centrifuged at 700 g for 30 min, and then incubated the specimen for 60 min. The cells were washed twice with phosphate-buffered saline (PBS), and cultured for 56 h. Cytopathic areas were evaluated and typed with specific mouse antiadenovirus monoclonal antibody (CHEMICON International Inc., CA, USA).
Preparation of PCR samples
A volume of 2 ml of urine was centrifuged at 15 000 g for 1 h at 41C. The sediment was suspended in 100 ml of PBS, and DNA was purified using a QIAmp DNA Blood Mini Kit (QIAGEN, Hilden, Germany), together with 2 ml of HC following RIST control cultured adenovirus type 11 (Ohtsuka Assay, Tokushima, Japan). A volume of 5 ml of purified DNA was subjected to PCR assay using a GeneAmp Kit (PerkinElmer, NJ, USA) and GeneAmp PCR System 9600 (Perkin-Elmer, CT, USA).
PCR specific for adenovirus and PCR specific for adenovirus type 11
Adenovirus-specific oligomers used in the PCR assay were AD185S (5-tccagcaacttcatgtccatgg-3) and AD185A (5-tcgatgacgccgcggt-3). After 40 cycles of PCR, the end products of 186 base pairs (bp) were electrophoresed on 3% agarose gel. The conditions for PCR were 941C for 5 min, 40 cycles of 941C for 60 s, 651C for 60 s, 721C for 1 min, and 721C for 7 min.
A nested PCR assay was performed with two primer sets. Adenovirus type 11-specific oligomers were selected from hexon gene. AD11BKOS (5-aatacaactggtgaggaacacgtaa cag-3) and AD11BXUA (5-ccgcatcaaaaaactccatgtcgatat cat-3) were used for the first PCR and AD11BXIS (5-tggaagtttcagatgaagaaagtaaaccga-3) and AD11BTIA (5-caaaggacccgtagcat-ggtttc-3) were used for the second PCR. After the first PCR, 2 ml of the product solution was processed in the second PCR. The final end product of 168 bp was electrophoresed on 3% agarose gel. The conditions for PCR were 941C for 5 min, 40 cycles at 941C for 60 s, 601C for 60 s, 721C for 1 min, and 721C for 7 min.
End points and statistical analysis
The primary end point of this study was the incidence of HC following RIST. Other objectives were to investigate the characteristics and risk factors for HC following RIST. The probability of HC was calculated as a function of time with the Kaplan-Meier method as of June 31st, 2002. The median follow-up period after transplantation was 252 days (range, 82-1046 days). Surviving patients were censored on the last day of follow-up.
A univariate analysis using the w 2 test and MannWhitney test was performed to identify risk factors for HC.
Variables examined in univariate analysis were sex, age, risk of underlying diseases, donor, HLA disparity, stem cell source, antiadenovirus and anti-CMV IgG antibody in recipients, previous use of interferon-alpha, type of transplantation, preparative regimens, GVHD prophylaxis, acute GVHD, chronic GVHD, use of corticosteroid, and CMV infection.
A Cox proportional-hazards analysis was conducted to determine whether a type of transplantation (CST vs RIST) was independently associated with HC development. Clinical variables examined in the univariate analysis entered in a backward, stepwise Cox's proportionalhazards model to identify predictors of HC development. The variables with P-values of less than 0.50 entered the model, and those with P-values of less than 0.10 were retained. These variables included sex, donor types, HLA disparity, stem cell sources, antiadenovirus IgG in recipients, previous use of interferon-alpha, total dose of BU, use of CY, use of ATG, use of methotrexate, acute and chronic GVHD, use of corticosteroid, and CMV infection. P-values less than 0.05 were considered to be significant.
Results
Patients' characteristics and the incidence of HC
Patients who underwent RIST tended to be older and have more advanced diseases than those who underwent CST ( Table 1 ). The actuarial frequency of HC development in the RIST group was 7.6% (9/119), which gave a cumulative annual incidence of 11.7%. In the CST group, 13 of 137 patients (9.5%) developed HC, giving an estimated annual incidence of 9.7%. The probability of developing HC, calculated by the Kaplan-Meier method, was similar between the two treatment groups (P ¼ 0.77) (Figure 1 ).
Clinical characteristics of HC
The severity of HC in the RIST group tended to be lower than that in the CST group (Table 2 ). In the RIST group, the duration of HC was significantly shorter and the red cell Table 1 Characteristics of patients (CST vs RIST) transfusion requirements were significantly less than those in the CST group. All of the patients with HC were treated supportively. Ribavirin is not approved in Japan, and therefore was not used in any of the patients. Of the 18 patients with grade II-III HC, 11 required continuous bladder irrigation and two required nephrostomy. HC completely improved without any sequelae following supportive measures in all of the patients, except for three who died of disease progression or GVHD before the resolution of hematuria. The median duration of HC was 47 days (6-135) in the CST group and 25 (10-35) days in the RIST group (P ¼ 0.016).
Viral etiology
Among the 22 patients with HC, the viral etiology was confirmed in 14 patients (Table 2 ). In the RIST group, the causative organisms were adenovirus (n ¼ 7) and BK virus (n ¼ 1). The diagnosis was either culture based (n ¼ 4) or PCR based (n ¼ 4). All four of the urine samples sent for serological and DNA typing revealed adenovirus type 11. Documented organisms, either by cultures (n ¼ 3) or PCR (n ¼ 3), in the CST group were adenovirus (n ¼ 5) and BK virus (n ¼ 1). Four infections of adenovirus were of type 11, and the other was unidentified. Thus, the viral etiology was identified more frequently in RIST than in the CST group (P ¼ 0.0743).
Risk factors
In the univariate analysis (Table 3) , antiadenovirus antibody positivity at transplantation, use of ATG and corticosteroid, the total dose of BU, and CMV infection all showed statistically significant associations with HC. The multivariate analysis showed that HC was significantly correlated with adenovirus anti-IgG antibody positivity, the total dose of BU, and a history of GVHD (Table 4) .
Discussion
RIST, a novel treatment modality, has been increasingly explored among patients who are ineligible for CST. While this approach is indeed curative in some patients with hematological or solid malignancies, there have been only a few published studies on complications after RIST. After CST, HC is a common, significant problem, and is supposedly affected by preparative chemotherapies, the presence of GVHD, and the intensity of immunosuppressive treatments.
The frequency of HC has been poorly studied, with results varying from 7 to 68%. [7] [8] [9] [10] [11] 25, [27] [28] [29] Even grading criteria for HC have not been established. 30 Most studies have diagnosed HC based on macroscopic hematuria, 11, 25, 27, 28 while in other studies a diagnosis of HC has been based on sustained microscopic hematuria. 15, 29, 31 In the present study, we defined HC as two or more episodes of macroscopic hematuria in patients with normal coagulation profiles and sterile urine, without any history/ evidence of renal stones or genitourinary malignancy. The CST (n=137) RIST (n=119) Cumulative incidence of hemorrhagic cystitis Figure 1 Probability of HC after transplant. The estimated 1-year probability of HC was 11.7 and 9.7% following RIST and CST, respectively. The probability of HC, calculated by the Kaplan-Meier method was similar in the two treatment groups (P ¼ 0.7695). Abbreviations: HC; hemorrhagic cystitis, CST; conventional hematopoietic stem cell transplantation.
HC following RIST
annual incidence of HC after RIST (11.7%) was not significantly different from that following CST (9.7%), and these were comparable to those in previous reports. 11, 25, 28 This study demonstrated that HC in RIST was as common as that in the CST group, despite the commonly accepted speculation that RIST carries fewer complications. We compared the clinical features of HC following RIST with those following CST ( Table 2 ). Although the rates of HC development were similar (Figure 1 ), HC after RIST tended to be milder, with lower blood transfusion requirements than those following CST. The duration of HC was also shorter in RIST than in CST. Urine samples were sent for bacterial, fungal, and viral cultures, and were subjected to PCR using adenovirusspecific primers at the diagnosis of HC. PCR assays for BK and JCV were not routinely performed, since they rarely cause HC in Japan. 25, 26 No bacteria or fungi were detected, whereas adenovirus (n ¼ 12) and BK virus (n ¼ 2) were evident among the 22 patients with HC. Our results support the notion that adenovirus is a principal pathogen of HC, and that the BK and JCV are rare in HC among Japanese patients. 25, 26 Contrary to the common belief that a nonmyeloablative regimen in RIST should lead to fewer infections, our study showed similar rates of infection between the RIST and CST groups. This may be related to profound immunodeficiency due to immunosuppressive treatments against GVHD or to GVHD per se.
The viral etiology was confirmed in 14/22 patients, indicating that it can play an important role in the pathogenesis of HC. However, it should be noted that any evidence of adeno-, BK, and JCV infection was not observed in the remaining eight patients, while PCR assay was utilized in this study. The causes of HC remain unknown in these patients. These findings suggest that viral infection alone does not invariably lead to HC in HSCT recipients, and that some viruses other than adeno-, BK and JCV, or unknown mechanism might have contributed to the pathogenesis of HC following transplant.
A multivariate analysis identified antiadenovirus IgG antibody positivity, the total dose of BU, and chronic GVHD as risk factors for HC after RIST (Table 4) . Adenovirus-associated diseases among immunocompromised hosts can be either primary infection 32 or reactivation of latent infection. 31, 33 Since two of the seven adenovirus-seronegative recipients developed adenoviruspositive HC, we cannot exclude the possibility of transmission via HSCT or blood transfusions. However, given the high prevalence and high rate of adenovirus-seropositivity prior to HSCT in Japan, the reactivation of latent infection may still be a major etiology for the development of HC. In fact, seven of 24 adenovirus-seropositive patients (29.2%) developed HC following HSCT, and its seropositivity was the strongest risk factor in our multivariate analysis. Screening for high-risk patients prior to HSCT could be beneficial in preventing HC.
There has been a debate over whether GVHD is a risk factor for HC. Ost et al 16 showed a close correlation between HC and acute GVHD. While three other reports have also found acute GVHD to be a risk factor, 29, 34, 35 Sencer et al 7 did not find an independent association by a multivariate analysis. In the present study, corticosteroid use was a significant risk factor (P ¼ 0.0005), and chronic GVHD had a marginal association (P ¼ 0.089) by a univariate analysis (Table 3) . Our multivariate analysis showed that chronic GVHD was a significant risk factor for HC (Table 4) . These factors are difficult to differentiate: acute and chronic GVHD are clinically linked, GVHD is uniformly treated with corticosteroid, and late-onset HC frequently overlaps with GVHD. Corticosteroid dose, which is an important matter to be discussed, also awaits further investigation. Furthermore, it is interesting that patients who had received ATG had a low risk for HC in this study (Table 3) , ATG usually reduces the incidences of GVHD, but carries a considerable risk of fatal infections. 22, 36 It is possible that ATG might promote reactivation of adenovirus, leading to the development of HC. However, our study is contrary to these assumptions. HC is associated with immunosuppression. At present, we can only safely conclude that patients treated with corticosteroid against GVHD are at high risk for HC after RIST.
The total dose of BU was another risk factor for HC after HSCT by our multivariate analysis (Table 4) , supporting the hypothesis that previous BU use could increase the risk of HC. 13 Atkinson et al 37 and Ringden et al 14 reported a higher rate of HC in patients conditioned with BU/CY, compared to those conditioned with CY/TBI, consistent with our results. BU might induce epithelial atypia in the bladder, contributing to the pathogenesis of late HC. 38 BU at 8 mg/kg, approximately half the dose used in CST, may still damage the uroepithelium, which could predispose patients to HC.
Although there were too few patients to draw firm conclusions, the present study revealed similar incidences of HC in the RIST and CST groups, and identified latent adenovirus infection, BU use in the preparative regimen and immunosuppression due to GVHD and/or corticosteroid to be risk factors for HC. However, whether viral infections contribute to an existing cystitis caused by GVHD remains to be studied. HC following RIST has clinical features similar to those of HC following CST, indicating that HC is a significant problem after RIST, as well as that after CST. While the exact mechanism of the development of HC remains unclear, clinicians should be able to alert this significant complication following RIST. Abbreviations: GVHD, graft-versus-host disease.
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